DEF: Achieve Life Sciences Seeks Stockholder Approval for Equity Incentive Plan Amendment at 2025 Annual Meeting

Achieve Life Sciences is holding its annual stockholder meeting on June 4, 2025, to elect directors, ratify the appointment of its accounting firm, and approve an amendment to its equity incentive plan.

Summary

• Achieve Life Sciences will hold its Annual Meeting of Stockholders virtually on June 4, 2025.
• Stockholders will vote on the election of seven directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and an amendment to the 2023 Non-Employee Director Equity Incentive Plan.
• The proposed amendment would increase the number of shares available for issuance under the equity incentive plan by 650,000 shares, bringing the total to 950,000 shares.
• The board recommends voting for all director nominees, the ratification of PwC, and the approval of the equity incentive plan amendment.
• The company had 34,685,072 shares of common stock outstanding as of April 15, 2025.
• The proxy statement and annual report are available online.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and factual manner. The positive sentiment stems from the company's efforts to attract and retain talent through equity compensation and its commitment to good corporate governance.

Positives

• The proposed amendment to the equity incentive plan aims to attract and retain qualified directors by offering competitive equity compensation.
• The virtual format of the annual meeting is expected to increase accessibility and lower costs.
• The board is actively engaged in risk oversight through its committees.
• The company has a Compensation Recovery Policy in place.

Negatives

• If the proposed amendment to the equity incentive plan is not approved, the company's ability to attract and retain qualified non-employee directors could be negatively impacted.
• The company has incurred significant net losses in recent years, as indicated in the Pay Versus Performance section.

Risks

• Failure to obtain stockholder approval for the equity incentive plan amendment could hinder the company's ability to attract and retain qualified directors.
• The company's reliance on equity awards to compensate directors and executives exposes it to potential dilution of existing stockholders' equity.
• The company faces risks related to cybersecurity threats, which are being monitored by the Audit Committee.

Future Outlook

The company expects the proposed Plan Amendment to be sufficient for two years and will grant the customary annual equity compensation paid to our non-employee directors on the date of each annual meeting of stockholders and any future one-time initial grants of equity awards.

Management Comments

• Richard Stewart, Chief Executive Officer, signed the proxy statement.
• The Board of Directors believes that the separation of the Chairman and Chief Executive Officer roles allows the Chief Executive Officer to focus his time and energy on operating and managing the Company and leverages the Chairmans experience and perspective.

Industry Context

The document indicates that offering an equity compensation program is vital to attracting and retaining highly skilled board members in the company's highly competitive industry.

Comparison to Industry Standards

• The Compensation Committee uses Aon's Human Capital Solutions to benchmark compensation against industry-appropriate peers.
• Base salaries are targeted to approximately the 50th percentile range of comparable peer companies in aggregate.
• Long-term equity incentive awards to the named executive officers are targeted at the market 50th to 75th percentile.

Management Changes

Corporate Governance

Related Party Transactions

• In May 2023, Contrarian Alpha, LP, a holder of more than 5% of our capital stock purchased 70,000 shares of our common stock, for an aggregate purchase price of $385,000.
• In February 2024, (a) Richard Stewart purchased 10,000 shares of our common stock and 10,000 warrants, for an aggregate purchase price of $45,850; (b) John Bencich, our former Chief Executive Officer, purchased 10,000 shares of our common stock and 10,000 warrants, for an aggregate purchase price of $45,850; and (c) Contrarian Alpha, LP purchased 100,000 shares of our common stock and 100,000 warrants, for an aggregate purchase price of $458,000.

Stakeholder Impact

• Approval of the equity incentive plan amendment could lead to dilution of existing stockholders' equity.
• The election of directors will determine the leadership and strategic direction of the company.
• The ratification of the independent accounting firm ensures the integrity of the company's financial reporting.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on June 4, 2025.
• The company will implement the approved proposals following the Annual Meeting.

Key Dates

Keywords

proxy statement, annual meeting, directors, equity incentive plan, stockholders, compensation, governance, PricewaterhouseCoopers, Achieve Life Sciences, shares